Genetic Data in Insurance Underwriting: Considerations in the Thai Context

Abstract

Whole-genome sequences contribute significantly to our understanding of human development and functions. Various abnormalities can result in diseases or reduce individuals' life expectancy. Utilizing genetic data for predicting an individual's health status is a consideration in insurance underwriting assessments. However, there is an ongoing debate about the appropriateness of using this information, given its unchangeable nature since birth. Discussions often center around the principles of the insurance premium setting and underwriting, which vary based on the applicant's health status and risk assessment.

There are two potential approaches. The first option is enacting laws. This would ensure that individuals are not discriminated against based on their genetic data. One consequence of this approach might be a significant increase in premium pricing for the overall portfolio. This could be due to the increased uncertainty for insurers when they cannot use genetic data to assess risks. Another option is discussion and agreement among concerned parties. This approach involves engaging in open discussions and reaching agreements among the relevant stakeholders. It allows for a more flexible and adaptable approach, where policies can be revised based on outcomes and experiences, especially if adverse events occur during a trial period.

Both options have their advantages and disadvantages. The best choice for Thailand will depend on what is considered most important and what aligns best with the country's specific circumstances and priorities. It's crucial to carefully weigh the implications and make a decision that serves the interests of all stakeholders involved.